← boardnext 2026-08-31next 2027-06
VSTM
Verastem, Inc.distress 5/10 · elevated risk$5.870%today-46% from 52w high
Oncology 3
Lead: NSCLC · target KRAS
Revenue
$19M
Liquidity
$188M
Runway
1.2 yrs
Shares 1y
+43%
Price & events
-12.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.4%
1D
+1.6%
1W
+39.3%
1M
-5.9%
3M
-8.1%
6M
+9.6%
1Y
+63.4%
2Y
-85.2%
5Y
-77.8%
All
Overview
- Market Cap
- $515.38M
- Enterprise Value
- $390.55M
- Volume
- 84.34K
- 52 Week Range
- $3.45 – $10.77
- Total Shares
- 87.87M
- Float Shares
- 70.38M
- Short %
- 27.64%
- % Held by Insiders
- 0.93%
- % Held by Institutions
- 98.27%
- RVOL
- 0.03x
- Beta
- 0.29
Pipeline stages · 2 programs
avutometinib, Defactinib, Pegylated liposomal doxorubicin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
VS-7375, Cetuximab, Carboplatin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 9 trials · 6 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08-31 Estimated 50% readout ~2026-10-15 | Phase 1/2 | avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel | KRAS Activating Mutation, Metastatic Cancer, Pancreas Cancer, Neoplasms Pancreatic, Malignant Neoplasm of Pancreas | — | active not recruiting |
| 2027-06 Estimated 50% readout ~2027-07-16 | Phase 2 | VS-7375, cetuximab, panitumumab | Colorectal Cancer | — | not yet recruiting |
| 2027-06 Estimated 50% readout ~2027-07-16 | Phase 2 | VS-7375, cetuximab | Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS | — | recruiting |
| 2027-06 Estimated 50% readout ~2027-07-16 | Phase 2 | VS-7375 | Non-Small Cell Lung Cancer | — | not yet recruiting |
| 2028-10-15 Estimated 50% readout ~2028-12-29 | Phase 3 | avutometinib, Defactinib, Pegylated liposomal doxorubicin | Low Grade Serous Ovarian Cancer | — | recruiting |
Show all 9 trials · 4 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-12 Estimated 50% readout ~2029-01-15 | Phase 1/2 | VS-7375, Cetuximab, Carboplatin | Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult, G12D Mutated KRAS | — | recruiting |
| 2026-06 | Phase 1/2 | avutometinib and sotorasib, avutometinib and sotorasib and defactinib | Non Small Cell Lung Cancer, KRAS Activating Mutation | 153 | active not recruiting |
| 2025-12-24 | Phase 1/2 | avutometinib (VS-6766) and adagrasib | Non Small Cell Lung Cancer, KRAS Activating Mutation, Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung, Malignant Neoplastic Disease | 85 | active not recruiting |
| 2025-12 | Phase 2 | Avutometinib (VS-6766), Defactinib (VS-6063) | Low Grade Serous Ovarian Cancer, Ovarian Cancer | 16 | active not recruiting |
Catalyst news & presentations · 19
- mid-2027Guided 55%readoutPhase 3avutometinib plus defactinib · Topline read-out of RAMP 301 primary endpointSEC 8-K
- first half of 2027Guided 55%trial initiationsecondaryPhase 3VS-7375 · Enroll first patient in Phase 3 pivotal trials.SEC 8-K
- mid-2027Guided 55%readoutPhase 3avutometinib; defactinib · Topline readout of RAMP 301 trialSEC 8-K
- second half of 2026Guided 55%readoutPhase 1/2VS-7375 · Report update on TARGET-D 101 trial.SEC 8-K
- 2026trial initiationsecondaryPhase 3avutometinib + defactinib · Registrational Phase 3 trial start in 2026SEC 8-K
- by the end of 2026Guided 40%enrollment completesecondaryPhase 2VS-7375 · Complete enrollment across all three TARGET-D Phase 2 trials.SEC 8-K
- 2H 2026Guided 55%trial initiationsecondaryVS-7375 · Select RP2D and initiate PDAC and NSCLC combination expansion cohortsSEC 8-K
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- 1H 2026trial initiationsecondaryPhase 1/2VS-7375 · Select RP2D and initiate monotherapy expansion cohortsSEC 8-K
- Q2 2026readoutavutometinib; defactinib · Update on safety and efficacy of RAMP 205 expansion cohortSEC 8-K
- mid-2026enrollment completesecondaryVS-7375 · Complete enrollment in combination dose-escalation cohortsSEC 8-K
- first half of 2026readoutPhase 1/2VS-7375 · Interim safety and efficacy updateSEC 8-K
- Q1 2026enrollment completesecondaryPhase 3avutometinib + defactinib · Complete enrollment of IDMC-recommended increaseSEC 8-K
- February 11, 2026conferencedata presentationsecondaryFireside chat at Guggenheim Emerging Outlook ConferenceSEC 8-K
- Q4 2025readoutPhase 2avutometinib + defactinib · Interim safety and efficacy from doublet and triplet combinationsSEC 8-K
- Q4 2025trial initiationsecondaryPhase 1/2VS-7375 · Initiate dose escalation cohorts with chemotherapy for PDAC and with chemotherapy plus anti-PD-1 for NSCLCSEC 8-K
- 2025-12-29trial discontinuedavutometinib · Discontinued RAMP 203 Phase 1/2 trial in advanced KRAS G12C-mutated NSCLC.SEC 8-K
- October 19, 2025 at ESMO 2025conferencedata presentationsecondaryPhase 1/2VS-7375 · Updated safety and efficacy data presented at ESMO 2025.SEC 8-K
- Sunday, September 7, 2025 from 12:00 to 1:15 pm (CEST)conferencedata presentationsecondaryPhase 1/2VS-7375 · Mini oral presentation of updated safety and efficacy data from Phase 1/2 studySEC 8-K
Approved drugs (1)
- AVMAPKI FAKZYNJA CO-PACK (COPACKAGED)AVUTOMETINIB POTASSIUM2025 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $15 (+156% upside) · 8 analysts
- 2026-07-07RBC CapitalOutperform
- 2026-07-02BTIGBuy
- 2026-06-24HC Wainwright & Co.Buy
- 2026-06-24BTIGBuy
- 2026-06-23JefferiesBuy
- 2026-05-14MizuhoOutperform
Competitors — KRAS
- none identified
Recent news
- 2026-07-23Verastem Oncology to report Q2 2026 results on Aug 6 - scanx.trade
- 2026-07-23Verastem Oncology Schedules Aug. 6 Webcast for Business Updates - Stock Titan
- 2026-07-22Verastem (VSTM) Launches TARGET-D 202 Trial for KRAS G12D Lung C - GuruFocus
- 2026-07-22Verastem's Phase 2 trial targets KRAS G12D, with no FDA-approved therapy - Stock Titan
- 2026-07-22Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer - Business Wire
- 2026-07-15Stop Battery Drain - VSTM Battery Disconnect Review And Installation Kylian Mbappé (WAmEhQGD0E) - Mshale
- 2026-07-15RBC Capital Reaffirms Outperform Rating For Verastem (VSTM) - Yahoo Finance
- 2026-07-15RBC Capital Reaffirms Outperform Rating For Verastem (VSTM) - Yahoo! Finance Canada
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.